

Disclosure Purpose: EV-22-00014

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Novo Nordisk	Other	Self
<p><i>Category:</i> Other <i>Additional Information:</i> Site principal investigator and enrolled participants for NN8022-4392 - Effect and safety of liraglutide 3.0 mg on weight management in children with obesity aged 6 to <12 years: 56-week, double-blind, randomized, placebo-controlled trial, Phase 3a. Funds were paid directly to my institution.</p>		<p><i>Description:</i> Clinical Trial</p>
VIVUS, Inc.	Other	Self
<p><i>Category:</i> Other <i>Additional Information:</i> Site principal investigator and enrolled participants for this trial "Phentermine/Topiramate Extended Release for the Treatment of Adolescent Obesity: A Randomized, Placebo-Controlled Trial." Funds were paid directly to my institution.</p>		<p><i>Description:</i> Clinical Trial</p>

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EV-22-00014

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Grant / Contract	Self
<i>Recipient Name:</i> Aaron Kelly <i>Grant / Contract Description:</i> Provision of drug and placebo for NIDDK-funded clinical trial <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Boehringer Ingelheim	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Unpaid Consultant
Eli Lilly and Company	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Unpaid consultant
Novo Nordisk	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> I am not certain about the start date. I believe it was prior to 2018 but the dropdown only allows out to 2018.		<i>Description:</i> Unpaid consultant (only travel expenses)
Orexigen Therapeutics, Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> I am uncertain about the start date but believe it was prior to 2018. However, the dropdown only allows out to 2018.		<i>Description:</i> Unpaid consultant
VIVUS, Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Aaron Kelly <i>Grant / Contract Description:</i> Donated drug/placebo for NIDDK-funded clinical trial <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
VIVUS, Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> I am uncertain about the start date but believe it was prior to 2018. However, the dropdown only allows out to 2018.		<i>Description:</i> Unpaid consultant
WW (formerly Weight Watchers)	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> I am uncertain about the start date but believe it was prior to 2018. However, the dropdown only allows out to 2018.		<i>Description:</i> Unpaid consultant

Certification

I certify that the information provided in this disclosure is complete and accurate.

Megan Oberle

Mar 16, 2022 15:45:48 EDT
NEJM Evidence

Disclosure Purpose: EV-22-00014

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: EV-22-00014

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
VIVUS, Inc.	Employment	Self
<i>Title:</i> Sr. Director, Clinical Research		<i>Position Description:</i> Oversaw design, operational conduct, and reporting of clinical trials sponsored by company.
<i>Additional Information:</i>		

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: EV-22-00014

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
VIVUS LLC	Employment	Self
<i>Title:</i> Associate Director, Clinical Operations <i>Additional Information:</i>		<i>Position Description:</i>

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: EV-22-00014

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
AstraZeneca	Grant / Contract	Self
<i>Recipient Name:</i> Vanderbilt University Medical Center <i>Grant / Contract Description:</i> Provided drug/placebo for an NIH funded study <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Radius Health, Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> One advisory board meeting in 2021, no ongoing involvement		<i>Description:</i> Served as a scientific advisor for development of a hypothalamic obesity clinical trial
Rhythm Pharmaceuticals	Grant / Contract	Self
<i>Recipient Name:</i> Vanderbilt University Medical Center <i>Grant / Contract Description:</i> Site PI for clinical trial in genetic obesity and hypothalamic obesity <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Rhythm Pharmaceuticals	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Consulted on development of a genetic obesity screening program and hypothalamic obesity clinical trial. Average 5 hours per year.		<i>Description:</i> Scientific advisor
Rhythm Pharmaceuticals	Other	Self
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> Speaker on Bardet Biedl Syndrome (patient and provider disease education, no product discussions)
Saniona A/S	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Advising on clinical trial study design for upcoming clinical trial. Approx. 5 hours per year.		<i>Description:</i> Hypothalamic Obesity Scientific Advisory Board
Soleno	Grant / Contract	Self
<i>Recipient Name:</i> Vanderbilt University Medical Center <i>Grant / Contract Description:</i> Site PI for clinical trial in Prader-Willi syndrome <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Vivus	Grant / Contract	Self
<i>Recipient Name:</i> Vanderbilt University Medical Center <i>Grant / Contract Description:</i> Site PI for clinical trial <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EV-22-00014

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
VIVUS, Inc.	Employment	Self
<i>Title:</i> Senior Vice President, Chief Medical Officer		<i>Position Description:</i> Responsible for Clinical Development, Medical Affairs, Pharmacovigilance, Regulatory Affairs, Quality Assurance, and Regulatory Compliance
<i>Additional Information:</i> Salaried Officer of the company		

Certification

I certify that the information provided in this disclosure is complete and accurate.